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Julio G. Peguero, Ivan Arenas, and Gervasio A. Lamasn
Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, FLa b s t r a c tMedical practitioners have treated atherosclerotic disease with chelation therapy for over 50 years. Lack of strong of evidence led
conventional practitioners to abandon its use in the 1960s and 1970s. This relegated chelation therapy to complementary and
alternative medicine practitioners, who reported good anecdotal results. Concurrently, the epidemiologic evidence linking xenobiotic
metals with cardiovascular disease and mortality gradually accumulated, suggesting a plausible role for chelation therapy. On the basis
of the continued use of chelation therapy without an evidence base, the National Institutes of Health released a Request for Applications
for a deﬁnitive trial of chelation therapy. The Trial to Assess Chelation Therapy (TACT) was formulated as a 2  2 factorial randomized
controlled trial of intravenous EDTA-based chelation vs. placebo and high-dose oral multivitamins and multiminerals vs. oral placebo.
The composite primary endpoint was death, reinfarction, stroke, coronary revascularization, or hospitalization for angina. A total of
1708 post-MI patients who were 50 years or older with a creatinine of 2.0 or less were enrolled and received 55,222 infusions of disodium
EDTA or placebo with a median follow-up of 55 months. Patients were on evidence-based post-MI medications including statins. EDTA
proved to be safe. EDTA chelation therapy reduced cardiovascular events by 18%, with a 5-year number needed to treat (NNT) of 18.
Prespeciﬁed subgroup analysis revealed a robust beneﬁt in patients with diabetes mellitus with a 41% reduction in the primary endpoint
(5-year NNT ¼ 6.5), and a 43% 5-year relative risk reduction in all-cause mortality (5-year NNT ¼ 12). The magnitude of beneﬁt is such
that it suggests urgency in replication and implementation, which could, due to the excellent safety record, occur simultaneously.
& 2014 Elsevier Inc. Open access under CC BY-NC-ND license.Background
Evidence of xenobiotic metal toxicity
Metals play an important role in human biology. Iron is
critical for oxygen transport in hemoglobin. Zinc is a critical
part of the angiotensin-converting enzyme metalloprotein.
But there are many metals that have no beneﬁcial role in
human biology. These metals have been referred to as heavy
metals or toxic metals. The terms are imprecise because
these deﬁnitions all relate to either speciﬁc chemical1016/j.tcm.2014.06.002
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Open access under CC BY-NC-ND license.properties or atomic weight or functional aspects in human
biology. We will use the term xenobiotic metal to refer to
those metals without any speciﬁc role in the human body.
The epidemiologic evidence that many xenobiotic metals
are toxic is robust. For example, arsenic, cadmium, lead, and
mercury are ranked among the top 10 on the current Agency
for Toxic Substances and Disease Registry Priority List of
Hazardous Substances. Arsenic, lead, and mercury are ranked
as the top 3 hazardous substances [1].
Within the cardiovascular system, xenobiotic metals have
been linked to worsening hypertension, atherosclerosis,at Mount Sinai Medical Center, 4300 Alton Road, Suite #2070A,
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disease (PAD). We highlight below two metals, lead and
cadmium, with demonstrated hazardous effects on human
health that could at least partially explain the beneﬁcial
effects of chelation therapy. EDTA chelates both of these
metals. We emphasize, however, that other mechanisms
may be at play and that extensive work will have to be
carried out to fully understand the mechanism of beneﬁt of
the TACT infusions. Incomplete mechanistic understanding,
of course, does not preclude selective clinical application.Lead
Lead is a toxic environmental pollutant, considered one of
the most abundant xenobiotic metals. The main sources of
exposure are contaminated water, air, food, or soil. Lead is
often acquired through occupational exposure, soldered
joints in water pipes, airborne emissions, lead-containing
food products, and the well-known lead-based paints [2].
Once absorbed, more than 90% of lead is accumulated in
the bone. The lead stored in bone can remain for many years
and be released years later into the blood stream, long after
exposure. Blood lead levels are the usual method of testing
for toxicity, but they only reﬂect recent exposure. In fact, the
levels of blood lead have been falling steadily since leaded
gasoline for road-driven vehicles was eliminated. However,
environmental exposure continues, and the cardiovascular
consequences are not restricted to high, recent exposure
levels.
Epidemiological studies have found associations between
elevated lead levels and the prevalence of cardiovascular
disease [3–9]. In 4 large population-based studies published
from the National Health and Nutrition Examination Survey
(NHANES), higher blood lead levels were found to be asso-
ciated with a more than 25% increased risk of all-cause
mortality, 55% increased risk of cardiovascular mortality,
and a 2-fold higher risk of mortality from stroke [5–8]. Other
important associations of high blood lead levels include
peripheral artery disease, dyslipidemia, and hypertension
[3,4,6,7,9]. These complications have been associated with
the upper limit of what is considered safe blood lead levels
for adults [5], suggesting that there may be no “safe” levels for
this toxic substance.
The mechanisms of lead toxicity are not fully understood.
Lead may cause endothelial dysfunction by binding and
inhibiting endothelial nitric oxide synthase and decreasing
nitric oxide production [10] Lead also creates reactive oxygen
species (ROS) that damage cell structures including DNA and
cell membranes. Lead can replace other metal cofactors
during enzymatic reactions, therefore altering or compromis-
ing the end product. In the mitochondria, lead can replace
zinc cofactor, halting the formation of hemoglobin and
accumulating toxic levels of aminolevulinic acid.Cadmium
Cadmium is an extremely toxic metal that does not have any
biological role in humans. Rechargeable batteries account forthe majority of cadmium industrial use presently. And their
safe disposal remains a challenge. Some plants, fruits, and
grains can avidly absorb cadmium from the soil and/or water,
creating another source of human exposure and toxicity [2].
Tobacco plants, for example, avidly take up cadmium in the
leaf. Hence smoking is the most important single source of
cadmium exposure in the general population [11,12].
There is robust literature on the association of cadmium
with cardiovascular disease [5,6,8,13–15]. For example, Tellez-
Plaza et al. recently reported a study of 3348 patients with
measurement of urinary cadmium. The patients were partic-
ipants in the Strong Heart Study, a large cohort of Native
Americans. Elevated levels of urinary cadmium were found to
increase the incidence of all-cause, cardiovascular, and cor-
onary heart disease mortality. These associations were found
to be stronger in patients with known diabetes [14], a ﬁnding
that presaged the TACT diabetes results. A systematic review
of 12 studies of cadmium exposure and clinical cardiovascu-
lar disease reported a positive association between cadmium
levels and coronary heart disease, stroke, and peripheral
artery disease (PAD). These associations were signiﬁcant after
adjusting for smoking status [15]. Similarly, Navas-Acien et
al. [6] studied the association between blood cadmium levels
and PAD. The investigators reported a 2.9-fold increase in the
prevalence of PAD when comparing the highest and lowest
quartiles of blood cadmium levels.
One toxic mechanism of cadmium is thought to be related
to the inhibition of endothelial and calcium–calmodulin
constitutive nitric oxide synthesis. Cadmium is also known
to increase oxidative stress by being a catalyst in the
formation of reactive oxygen species, increasing lipid perox-
idation, and depleting glutathione and protein-bound sulf-
hydryl groups [6].Other xenobiotic metals
In 2011, Agarwal et al. [16] retrospectively studied the associ-
ation of metals with cardiovascular and cerebrovascular dis-
ease. Multivariable analyses found independent associations
between the combined endpoint and increased levels of anti-
mony, cadmium, cobalt, and tungsten. This study is important,
not only because it highlights the effect of cadmium on
cardiovascular disease but also because of the wide net it casts
over other metals, implicating them in cardiovascular disease
as well. And more to the point of this review, EDTA chelates
these metals. However EDTA does not chelate all metals
associated with cardiovascular disease. It is a weak chelating
agent for arsenic and does not effectively chelate mercury.Metals and diabetes mellitus
Diabetes mellitus is a well-known risk factor for developing
early cardiovascular disease and mortality [17]. The evidence
that xenobiotic metals are involved in the development of
vascular complications of diabetes has several sources.
Firstly, epidemiological evidence, recently reported, suggests
that the vascular complications of arsenic and cadmium are
more prominent in patients with diabetes [14,18].
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for the non-enzymatic production of reactive oxygen species
and formation of most advanced glycation end products
(AGEs), advanced lipoxygenation end products (ALEs), and
protein oxidation products. This is quite important, since the
formation of these oxidation products, particularly AGEs,
appears to be a plausible explanation for the development
of complications of diabetes [19,20]. Other transitional xeno-
biotic metals have also been found to be capable of catalyzing
AGEs and AGE byproducts [21,22]. During AGE metabolism,
the metals are neither discarded nor consumed. They con-
tinue to exist in cationic form, able to participate in subse-
quent reactions.
The third line of evidence implicating metal chelation in
the prevention of complications of diabetes stems from the
little known ﬁnding that some medications commonly rec-
ognized as reducing complications of diabetes have been
found to inhibit the Maillard reaction and the formation of
AGEs via metal chelation [23]. Thus, in light of this basic and
epidemiologic work, it is not surprising that metal chelation
should show additional beneﬁt in patients with diabetes.Chelation
When a molecule, either organic or inorganic, has the
potential to form two or more stable bonds with a single
metal atom, it is called a chelator, chelating agent, or
chelating ligand. This new complex is usually a non-ionic
molecule that is more stable, soluble, and resists dissociation.
The word chelation comes directly from the Greek root khele,
which means “claw.” This term accurately describes the
claw-like molecular structure and the enhanced metal afﬁn-
ity exhibited by chelating ligands when compared to other
non-chelating molecules. A good example of an organic
chelator is the porphyrin ring, which in turn, chelates the
iron molecule and forms a chelate complex called the heme
molecule. There are many organic and synthetic chelators.
Many chelating ligands were synthesized speciﬁcally for
binding certain metals. These compounds show enhanced
chelating properties towards their targets. Important exam-
ples of synthetic chelators currently in use are dimercaprol
(BAL), dimercaptosuccinic acid (DMSA), deferoxamine, and
various salts of ethylenediamine tetraacetic acid (EDTA).
EDTA is a synthesized amino acid with strong, non-speciﬁc
chelating properties for valences of þ2 to þ6. The EDTA–
metal chelate is water soluble and typically excreted in the
urine. It can form strong covalent bonds with some xeno-
biotic metals and increase the urinary excretion of calcium,
zinc, cadmium, and lead [24]. Its afﬁnity to calcium led to the
early hypothesis that EDTA might decalcify atherosclerotic
plaque.Application of EDTA to treat atherosclerosis
In the 1950s, Clarke et al. tested the effect of EDTA in a group
of patients with severe angina and found remarkable symp-
tomatic and/or electrocardiographic improvement after
repeated EDTA infusions in 17 out of 20 patients [25].Following these observations, and despite the lack of well-
powered clinical trials to evaluate its efﬁcacy, the use of
EDTA to treat angina and other forms of atherosclerotic
disease continued to increase in the following 50 years after
Clarke's initial report. This uncontrolled use led to many case
reports and case series, some of them extensive, supporting
EDTA chelation for cardiovascular disease. These case
reports could, at best, be interpreted only as hypothesis
generating.
Three small randomized studies, 2 in claudication [26,27]
and one in angina [28], encompassing 269 patients in aggre-
gate tested the role of chelation therapy for atherosclerotic
disease. These studies were underpowered to detect small to
moderate clinical beneﬁts of chelation therapy on the surro-
gate endpoint of exercise capacity, and none evaluated
meaningful clinical endpoints such as cardiac events or
mortality.
However, these ﬁndings were interpreted by some authors
as evidence against the efﬁcacy of chelation therapy [29]. Yet
the absence of evidence of efﬁcacy did not constitute evi-
dence of absence of chelation's efﬁcacy. A small or moderate
beneﬁt of EDTA chelation particularly with regards to clinical
endpoints, could not be excluded [30].
In fact, a 2002 Cochrane systematic review on the role of
chelation therapy in coronary heart disease concluded that
the existing body of work on chelation therapy and coronary
heart disease was insufﬁcient to recommend for or against its
use [31]. Nevertheless, in 2007 more than 100,000 adults in
United States were using this form of therapy [32], which
could potentially cause severe hypocalcemia and death when
misused [33]. It was in this context of uncertainty and in
large, to respond to the public health question posed by EDTA
chelation therapy, that the Trial to Assess Chelation Therapy
(TACT) was born [34]. Thus, after nearly 50 years of empirical
use of chelation therapy for atherosclerosis, TACT was the
ﬁrst randomized trial designed to evaluate the effects of an
EDTA-based chelation regimen on clinical outcomes in
patients with coronary disease.Overview of the TACT protocol
The TACT investigators were tasked with testing the most
prevalent chelation treatment as used in the community.
Thus, a 10-component solution (Table 1) was now the stand-
ard. In addition, the EDTA-based chelation solution was also
typically administered with high doses of oral multivitamins
and multiminerals (MVM). In order to prevent confounding
and understand the interaction of the chelation solution with
oral supplements, the trial was designed as a 2  2 factorial
[34]. Patients were randomly assigned to 4 groups:1. Active intravenous (IV) chelation infusions þ active oral
MVM.2. Active IV chelation infusions þ placebo oral MVM.
3. Placebo IV chelation infusions þ active oral MVM.
4. Placebo IV chelation infusions þ placebo oral MVM.
Chelation-based infusions or placebo were administered
40 times: 30 weekly infusions, followed by 10 maintenance
Table 1 – Chelation infusion contents. The dose of EDTA
changes on estimated GFR; the maximum dose is 3 g.
Additive
2 g of magnesium chloride
100 mg of procaine HCL
2500 Units of unfractionated heparin
7 g of ascorbate
2 mEq KCl
840 mg sodium bicarbonate
250 mg pantothenic acid
100 mg of thiamine
100 mg of pyridoxine
QS with sterile water to 500 ml
Adapted with permission from Lamas et al. [34].
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placebo was administered throughout the course of the
trial.
Eligible patients were at least 50 years old, had experienced a
myocardial infarction (MI) 6 weeks or more prior to enroll-
ment, and had a serum creatinine of 2.0 mg/dL or less. The
primary endpoint was a composite of death from any cause,
reinfarction, stroke, coronary revascularization, or hospital-
ization for angina. The composite of cardiovascular death,
reinfarction, or stroke was a prespeciﬁed secondary endpoint,
as was quality of life. Treatment comparisons were performed
according to the intention-to-treat principle and included all
patients in the group to which they were randomized.
The statistical plan originally called for 2372 patients to
have 85% power to detect a 25% difference in the primary
endpoint. During the course of enrollment, it became clear
that 1700 patients followed up for a longer period was a more
realistic goal. Thus, 1708 patients followed up a median of 55
months maintained the same statistical power.Results of TACT—Overall population
The ﬁrst patient was enrolled in September 2003 and TACT
was unblinded in August 2012. A total of 1708 patients were
enrolled and randomized (839 patients to chelation and 869
patients to placebo) at 134 sites, of which 81 (60%) were sites
in which chelation therapy was already practiced. Patients
received a total of 55,222 infusions. The median number of
infusions received was 40 (IQR ¼ 30–40); 76% of patients
completed at least 30 infusions and 65% completed all 40Table 2 – TACT summary of results.
Population Endpoint Treatment comparison
Overall Primary EDTA vs. placebo
Overall Primary EDTA þ oral MVM vs. placebo þ pla
Diabetes Primary EDTA vs. placebo
Diabetes Death EDTA vs. placebo
Diabetes Primary EDTA þ oral MVM vs. placebo þ pla
MVM ¼ multivitamins and multiminerals; NNT ¼ number needed to tre
Primary endpoint ¼ death, MI, stroke, coronary revascularization, and hinfusions. The median duration of follow-up was 55 (IQR ¼
26–60) months overall. Active treatment patients were fol-
lowed up for 56 (IQR ¼ 28–60) months and placebo patients
were followed up for 53 (IQR ¼ 24–60) months.TACT population
The median age was 65 (IQR ¼ 59–72) years, 18% were women,
9% were minority, and the median body mass index was 30.
The qualifying MI had occurred a median of 4.6 (IQR ¼ 1.6–9.2)
years prior to enrollment. The study population had a high
prevalence of self-declared diabetes (31%), prior coronary revas-
cularizations (83%), and high use of guideline-recommended
medications such as aspirin (84%), β-blockers (72%), and statins
(73%). Patients had a median fasting glucose level of 102 (IQR ¼
92–121) mg/dL and a low-density lipoprotein cholesterol (LDL-
C) level of 89 (IQR ¼ 67–115) mg/dL. Fasting blood sugar did not
change over time with EDTA infusions compared with placebo.Overview of publications
The initial TACT publication compared EDTA-based chelation
with placebo infusions. Follow-up publications have reported
on the oral MVM comparison, analysis of the 4 factorial
groups, and an analysis of the subgroup of patients with
diabetes (Table 2).Comparison of chelation with placebo infusions
The primary endpoint occurred in 222 (26%) of the chelation
group and 261 (30%) of the placebo group [35]. The Kaplan–
Meier 5-year estimates for the primary endpoint were 32.8%
(95% CI ¼ 29.1–36.5%) in the chelation group and 38.5% (95%
CI ¼ 34.6–42.3%) in the placebo group (HR ¼ 0.82; 95% CI ¼
0.69–0.99; p ¼ 0.035) (Fig. 1). The 5-year number needed to
treat (NNT) to prevent an event was 18. The statistical goal of
the trial had been met. The effect of EDTA chelation on the
components of the primary endpoint other than death was of
similar magnitude as its overall effect. Finally, the event
curves continued to separate after the infusions ended at
about 14 months, suggesting the continued effect of chelating
a metal toxin that might have taken a lifetime to accumulate.
Chelation therapy reduced cardiovascular outcomes in a
secondary prevention population.HR 95% CI p 5-yr NNT
0.82 0.69–0.99 0.035 18
cebo 0.74 0.57–0.95 0.016 12
0.59 0.44–0.79 0.0002 6.5
0.57 0.36–0.88 0.011 12
cebo 0.49 0.33–0.75 o0.001 5.5
at to prevent an event.
ospitalization for angina.
Fig. 1 – Kaplan–Meier estimates of the primary composite endpoint, EDTA chelation therapy vs placebo. (Adapted with
permission from Lamas et al. [35].)
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The analysis of the 4 factorial groups is particularly important
because it evaluates chelation therapy as it is practiced in the
community and allows one to tease out the individual
components (chelation, MVM, both, or neither) of beneﬁt, if
present. Overall, there was a stepwise reduction with the
addition to double placebo of oral MVM, or chelation, or both.
The 5-year Kaplan–Meier event rate estimate for the primary
endpoint was 31.9% in the chelation þ high-dose vitamin
group, 33.7% in the chelation þ placebo vitamin group, 36.6%
in the placebo infusion þ active vitamin group, and 40.2% in
the placebo infusions þ placebo vitamin group (Fig. 2) [36].
The primary endpoint by treatment group occurred in 139
(32%) of the placebo infusion þ placebo vitamin group and
108 (26%) of patients in the chelation þ high-dose vitamin
group. The comparison of active infusion þ active vitamins
with placebo infusions þ placebo vitamins was signiﬁcant
(HR ¼ 0.74, 95% CI ¼ 0.57–0.95; p ¼ 0.016) (Fig. 2). The absolute
difference in 5-year Kaplan–Meier estimated event rates
between placebo–placebo and active–active groups was 8.3%
and the number needed to treat (NNT) to prevent 1 event over
5 years was 12 (Table 2). Thus, EDTA chelation plus MVM on a
background of optimal medical therapy offered important
beneﬁts when compared to optimal medical therapy, includ-
ing statins, alone.Analysis of patients with diabetes
Diabetes mellitus was prespeciﬁed as a subgroup for analysis
in TACT. A total of 633 (37%) patients enrolled in the study
met the deﬁnition of diabetes mellitus. Treatment with EDTA
infusions reduced the primary endpoint (EDTA chelation vs.
placebo: 25% vs. 38%; HR ¼ 0.59; 95% CI ¼ 0.44–0.79; p o
0.0002) [37]. The Kaplan–Meier curves again continued to
diverge after the infusions stopped, indirectly supporting
the metal chelation hypothesis. There was a 15% absolutedecrease in the 5-year Kaplan–Meier primary event rate
(Fig. 3) and a 41% relative reduction in risk. The 5-year NNT
was 6.5 (95% CI ¼ 4.4–12.7) (Table 2). There were important
and consistent reductions in the components of the primary
endpoint as well. Rates of the principal secondary endpoint,
cardiovascular death, MI, or stroke were also lower for
diabetic patients randomized to EDTA chelation (HR ¼ 0.60;
95% CI ¼ 0.39–0.91; p ¼ 0.017), with a 5.1% absolute decrease
in the 5-year Kaplan–Meier event rate and a relative reduction
of 40%. Patients with diabetes mellitus randomized to EDTA
chelation had a signiﬁcant reduction in recurrent MI (HR ¼
0.48; 95% CI ¼ 0.26–0.88; p ¼ 0.015), in all-cause mortality
(HR ¼ 0.57; 95% CI ¼ 0.36–0.88; p ¼ 0.011; Fig. 4; 5-year NNT ¼
12; Table 2), and in coronary revascularizations (HR ¼ 0.68;
95% CI ¼ 0.47–0.99; p ¼ 0.042). Furthermore, in the factorial
analyses comparing chelation þ active vitamins with placebo
infusions þ placebo oral vitamins, the primary endpoint
occurred in 56 (38%) of the placebo infusion þ placebo vitamin
group and 36 (23%) of patients in the chelation þ high-dose
vitamin group (HR ¼ 0.49, 95% CI ¼ 0.33, 0.75; po 0.001, Fig. 5),
with a 5-year NNT ¼ 5.5 (Table 2) [36].Safety of chelation therapy
TACT also showed that, as used in the trial, treatment with
EDTA was safe. EDTA was associated with few side effects,
and there were no differences in serious adverse events
compared with placebo. Hypocalcemia, deﬁned as a calcium
level less than 8.5 mg/dL prior to an infusion, was reported in
52 chelation patients (6.2%) and 30 placebo patients (3.5%)
(p ¼ 0.008). One patient had symptomatic hypocalcemia
associated with muscle cramping that led to an emergency
department visit.TACT in context
TACT is a unique trial that crossed rigid lines of scientiﬁc
thought. Its scientiﬁc basis is decades deep. The association
Fig. 2 – 5-Year Kaplan–Meier event rate estimates for the primary composite endpoint for the four factorial groups. (Adapted
with permission from Lamas et al. [36].)
Fig. 3 – Adapted with permission from Escolar et al. [37].
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Fig. 4 – Mortality from any cause in diabetes mellitus by infusion group. Adapted with permission from Escolar et al. [37].
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is the participation of metal-catalyzed oxygen chemistry in
the production of AGEs. But this knowledge has been held in
silos—in environmental health, epidemiology, and diabetesFig. 5 – 5-Year Kaplan–Meier event rate estimates for the prima
Placebo–placebo. (Adapted with permission from Lamas et al. [3basic science—silos the cardiologist does not often visit.
Thus, TACT serendipitously served as a logical clinical test
of these lines of knowledge. As such, the results have
unveiled an exciting area of new cardiovascular researchry composite endpoint in diabetic patients. Active–active vs.
6].)
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modiﬁable risk factor for cardiovascular disease. Despite the
epidemiological association between xenobiotic metals and
cardiovascular disease, and the presumed effect of EDTA
removing these toxins; the exact mechanism of how chela-
tion reduced major cardiovascular events is still unknown.
Indeed, the positive effect of high doses of vitamin C on
vascular endothelium should not be neglected as a potential
contributing agent.
The TACT results, also, must be placed in context. In a 2006
review of statin therapy [38], the 5.1-year NNT for major
cardiovascular events in a secondary prevention population,
an endpoint similar to TACT, was 15. For chelation þ oral
vitamins, it was 12. Even more striking is the effect on
patients with diabetes. The 5.1-year NNT for major coronary
events for statins was 17, for the TACT infusion treatment
alone, 6.5 (5-year NNT). These striking results of a 10 year NIH
trial encourage future study, but leave the clinician wishing
for early, selective implementation.Conclusions
Among patients with a prior MI, a regimen of 40 infusions of
disodium EDTA-based infusions safely reduced cardiovascu-
lar events in a post-MI population, suggesting that xenobiotic
metal pollutants are cardiovascular risk factors. The effect of
the chelation infusions was enhanced with high doses of oral
multivitamins and multiminerals. The therapeutic beneﬁt
was particularly striking in diabetic patients. These results
were observed against a background of modern evidence-
based post-MI therapy.Future research
At present, the unique nature of these ﬁndings demands
follow-up research to replicate ﬁndings and understand
mechanisms. Such research should take place in patients
with diabetes and macrovascular disease, including periph-
eral artery disease. The xenobiotic metal hypothesis that we
have described should be tested, as should the development
of AGEs and RAGE activation. Additionally, pragmatic,
patient-oriented outcome trials, comparing traditional treat-
ment of severe PAD with standard care plus chelation could
be carried out. Because of the generic nature of this inter-
vention, there is absolutely no pharmaceutical company
interest in this therapy, so all of us await NIH initiatives.
Still, the magnitude of beneﬁt was such that it suggests
urgency in replication and implementation, which could,
due to the excellent safety record, occur soon simultaneously.
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